Revelation Biosciences Inc (REVB)

$1.05 +0.02 (1.94%)
Market Cap 4.07M
Revenue (ttm) 0.00
Net Income (ttm) -8.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 22,027
Avg Vol 51,808
Day's Range N/A - N/A
Shares Out 3.91M
Stochastic %K 53%
Beta -0.09
Analysts Strong Sell
Price Target $19.25

Company Profile

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 800 3717
Address:
4660 La Jolla Village Drive, Suite 100, San Diego, United States
qlox
qlox Jun. 30 at 10:17 PM
$REVB REVB 2 to 250 3.72 Vote Approved
0 · Reply
qlox
qlox Jun. 30 at 10:16 PM
$REVB 1:125 reverse split coming
0 · Reply
apache007
apache007 Jun. 30 at 9:04 PM
$REVB date for delist this? please
0 · Reply
revuelto
revuelto Jun. 16 at 4:00 PM
$REVB seems to be gravitating toward a delisting…..
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 11:46 AM
$REVB
0 · Reply
urgetosurge
urgetosurge Jun. 3 at 3:39 PM
$REVB looks like this is finally setting set up for the shorts. Compliance issues ahead imo.
0 · Reply
urgetosurge
urgetosurge May. 27 at 3:12 PM
$REVB umm, is this company tone deaf? Sure seems like it.
0 · Reply
urgetosurge
urgetosurge May. 22 at 6:38 PM
$REVB looks like corporates going to miss the ebola opportunity?? It'll still be a hot sector but for how long?
0 · Reply
urgetosurge
urgetosurge May. 22 at 10:02 AM
$REVB per Schwab there's 3.9 outstanding. 4.2 market cap, boom value of 3.32. Ebola related latent play. 52 week high of 30.
0 · Reply
urgetosurge
urgetosurge May. 20 at 10:38 PM
$REVB stocks has a lot of room to run here. Only 3 million outstanding. Easy below book value appreciation. Pivotal news release and we're off!
0 · Reply
Latest News on REVB
Revelation Biosciences Transcript: Transcript

Jun 16, 2026, 1:07 AM EDT - 15 days ago

Revelation Biosciences Transcript: Transcript

Revelation Biosciences Earnings release

Jun 12, 2026, 4:32 AM EDT - 19 days ago

Revelation Biosciences Earnings release

Revelation Biosciences Earnings release

Jun 12, 2026, 4:23 AM EDT - 19 days ago

Revelation Biosciences Earnings release

Revelation Biosciences adds two new members to AKI Advisory Board

2026-06-01T13:56:20.000Z - 4 weeks ago

Revelation Biosciences adds two new members to AKI Advisory Board

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

Jun 1, 2026, 9:00 AM EDT - 4 weeks ago

Revelation Biosciences Expands Acute Kidney Injury Advisory Board

Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year

2026-05-11T13:48:22.000Z - 7 weeks ago

Revelation Biosciences reports FY25 EPS ($14.35) vs ($1,052.16) last year

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

May 11, 2026, 9:00 AM EDT - 7 weeks ago

Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 7 weeks ago

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences announces formation of AKI advisory board

2026-04-06T13:18:58.000Z - 3 months ago

Revelation Biosciences announces formation of AKI advisory board

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Apr 6, 2026, 9:00 AM EDT - 3 months ago

Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board

Revelation Gemini data show ‘broad effect,’ says Roth Capital

2026-03-30T19:56:44.000Z - 3 months ago

Revelation Gemini data show ‘broad effect,’ says Roth Capital

Revelation Biosciences presents additional data from Prime Clinical Study

2026-03-30T13:21:15.000Z - 3 months ago

Revelation Biosciences presents additional data from Prime Clinical Study

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

Mar 30, 2026, 9:00 AM EDT - 3 months ago

Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Mar 24, 2026, 9:00 AM EDT - 3 months ago

REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Mar 19, 2026, 9:00 AM EDT - 3 months ago

Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference

Revelation Biosciences price target lowered to $16 from $20 at Roth Capital

2026-02-27T13:39:33.000Z - 4 months ago

Revelation Biosciences price target lowered to $16 from $20 at Roth Capital

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Feb 26, 2026, 4:15 PM EST - 4 months ago

Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025

Revelation Biosciences files to sell 4.27M shares of common stock for holders

2026-01-30T21:10:32.000Z - 5 months ago

Revelation Biosciences files to sell 4.27M shares of common stock for holders

Revelation Biosciences Inc trading halted, news pending

2026-01-28T00:50:09.000Z - 5 months ago

Revelation Biosciences Inc trading halted, news pending

Revelation Biosciences announces 1-for-4 reverse stock split

2026-01-26T15:01:09.000Z - 5 months ago

Revelation Biosciences announces 1-for-4 reverse stock split

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

Jan 26, 2026, 9:55 AM EST - 5 months ago

Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

Jan 23, 2026, 2:10 PM EST - 5 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds

Revelation reaches agreement with FDA on Gemini approval pathway

2026-01-21T13:51:28.000Z - 5 months ago

Revelation reaches agreement with FDA on Gemini approval pathway

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

Jan 21, 2026, 8:30 AM EST - 5 months ago

Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Jan 14, 2026, 9:00 AM EST - 6 months ago

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 12, 2026, 5:00 PM EST - 6 months ago

Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Revelation Biosciences initiates GMP manufacturing of GEMINI

2026-01-07T14:17:33.000Z - 6 months ago

Revelation Biosciences initiates GMP manufacturing of GEMINI

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Jan 7, 2026, 9:00 AM EST - 6 months ago

Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development

Revelation Biosciences reaches quorum for Dec. 3 special meeting

2025-12-01T14:15:23.000Z - 7 months ago

Revelation Biosciences reaches quorum for Dec. 3 special meeting

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

Dec 1, 2025, 9:00 AM EST - 7 months ago

Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting

Revelation Biosciences on track for end-of-phase 1 meeting later this year

2025-11-20T14:15:40.000Z - 7 months ago

Revelation Biosciences on track for end-of-phase 1 meeting later this year

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Nov 20, 2025, 9:00 AM EST - 7 months ago

Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Nov 6, 2025, 4:15 PM EST - 8 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025

Revelation Biosciences announces cancellation of Special Meeting

2025-10-29T13:15:56.000Z - 8 months ago

Revelation Biosciences announces cancellation of Special Meeting

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Oct 29, 2025, 9:00 AM EDT - 8 months ago

Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Oct 15, 2025, 5:00 PM EDT - 9 months ago

Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025

Revelation Biosciences files to sell 13.07M shares of common stock for holders

2025-09-16T21:20:13.000Z - 10 months ago

Revelation Biosciences files to sell 13.07M shares of common stock for holders

Revelation Biosciences announces exercise of warrants for $9.6M in proceeds

2025-09-11T12:40:32.000Z - 10 months ago

Revelation Biosciences announces exercise of warrants for $9.6M in proceeds

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Sep 11, 2025, 8:30 AM EDT - 10 months ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

Revelation Biosciences announces webcast to review Phase 1b PRIME data

2025-09-10T11:30:36.000Z - 10 months ago

Revelation Biosciences announces webcast to review Phase 1b PRIME data

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Sep 10, 2025, 7:20 AM EDT - 10 months ago

Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Sep 9, 2025, 4:55 PM EDT - 10 months ago

Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

Revelation Biosciences announces topline results from PRIME study

2025-09-09T12:35:01.000Z - 10 months ago

Revelation Biosciences announces topline results from PRIME study

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Sep 9, 2025, 8:00 AM EDT - 10 months ago

Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

Revelation Biosciences reports Q2 EPS ($7.01) vs. ($246.27) last year

2025-08-08T10:51:32.000Z - 11 months ago

Revelation Biosciences reports Q2 EPS ($7.01) vs. ($246.27) last year

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Aug 8, 2025, 6:30 AM EDT - 11 months ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Jul 24, 2025, 9:00 AM EDT - 1 year ago

Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Jul 16, 2025, 9:00 AM EDT - 1 year ago

Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Jul 1, 2025, 5:26 PM EDT - 1 year ago

Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

May 29, 2025, 4:05 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 29, 2025, 8:00 AM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 23, 2025, 4:05 PM EDT - 1 year ago

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

May 8, 2025, 4:15 PM EDT - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Apr 29, 2025, 9:00 AM EDT - 1 year ago

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Mar 17, 2025, 6:00 AM EDT - 1 year ago

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Mar 13, 2025, 6:00 AM EDT - 1 year ago

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Mar 6, 2025, 4:15 PM EST - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Feb 26, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Feb 24, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Jan 24, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Jan 21, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Jan 13, 2025, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Jan 6, 2025, 6:00 AM EST - 1 year ago

Nasdaq Grants Revelation Biosciences Inc. Continued Listing

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Dec 3, 2024, 8:38 AM EST - 1 year ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Dec 2, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Nov 12, 2024, 6:00 AM EST - 1 year ago

Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Nov 8, 2024, 4:15 PM EST - 1 year ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Sep 24, 2024, 6:00 AM EDT - 1 year ago

Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Aug 21, 2024, 5:30 PM EDT - 2 years ago

Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Aug 9, 2024, 4:15 PM EDT - 2 years ago

Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024

Revelation Biosciences Earnings release: Q2 2024

Aug 9, 2024, 7:00 AM EDT - 2 years ago

Revelation Biosciences Earnings release: Q2 2024

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Jun 24, 2024, 9:00 AM EDT - 2 years ago

Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

Jun 13, 2024, 9:21 AM EDT - 2 years ago

Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini

qlox
qlox Jun. 30 at 10:17 PM
$REVB REVB 2 to 250 3.72 Vote Approved
0 · Reply
qlox
qlox Jun. 30 at 10:16 PM
$REVB 1:125 reverse split coming
0 · Reply
apache007
apache007 Jun. 30 at 9:04 PM
$REVB date for delist this? please
0 · Reply
revuelto
revuelto Jun. 16 at 4:00 PM
$REVB seems to be gravitating toward a delisting…..
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 15 at 11:46 AM
$REVB
0 · Reply
urgetosurge
urgetosurge Jun. 3 at 3:39 PM
$REVB looks like this is finally setting set up for the shorts. Compliance issues ahead imo.
0 · Reply
urgetosurge
urgetosurge May. 27 at 3:12 PM
$REVB umm, is this company tone deaf? Sure seems like it.
0 · Reply
urgetosurge
urgetosurge May. 22 at 6:38 PM
$REVB looks like corporates going to miss the ebola opportunity?? It'll still be a hot sector but for how long?
0 · Reply
urgetosurge
urgetosurge May. 22 at 10:02 AM
$REVB per Schwab there's 3.9 outstanding. 4.2 market cap, boom value of 3.32. Ebola related latent play. 52 week high of 30.
0 · Reply
urgetosurge
urgetosurge May. 20 at 10:38 PM
$REVB stocks has a lot of room to run here. Only 3 million outstanding. Easy below book value appreciation. Pivotal news release and we're off!
0 · Reply
urgetosurge
urgetosurge May. 20 at 8:37 PM
$REVB ah or pre news cometh.
0 · Reply
urgetosurge
urgetosurge May. 20 at 7:15 PM
$REVB
0 · Reply
urgetosurge
urgetosurge May. 20 at 7:05 PM
$REVB latent ebola play, should run soon.
0 · Reply
7traderja
7traderja May. 12 at 2:06 PM
$REVB squeeze play?
0 · Reply
revuelto
revuelto May. 11 at 4:16 PM
$REVB they have lost the nasdaq time privilege after repeated aggressive r/s…ultimate delisting showdown is coming fast…newbies should probably use this zombie stock as a study for shortselling strategies
0 · Reply
MrResearch
MrResearch May. 8 at 7:22 PM
$REVB bounce higher!!
0 · Reply
knightseeker
knightseeker May. 8 at 4:19 PM
$REVB Could be a high risk swing trade here, looks like we could see a move up. Zacks Valuation at $22.50 https://s27.q4cdn.com/906368049/files/News/2026/Zacks_SCR_Research_05082026_REVB_Sorensen.pdf
0 · Reply
ZacksSCR
ZacksSCR May. 8 at 4:04 PM
$REVB Poised for Big Year https://buff.ly/uhPnpJE
0 · Reply
MMitchmoney
MMitchmoney May. 6 at 10:42 PM
$REVB I sold took the loss 📉 I let it bleed out for 3weeks with no sign of improvement thats all im willing to do Good luck to anyone here 🫡
0 · Reply
revuelto
revuelto May. 5 at 5:53 PM
$REVB short it all you want…this is a sham operation designed to siphon money from retail investors to enrich financing partners 😀..
0 · Reply
Schizoo
Schizoo May. 1 at 4:39 PM
$REVB is this thing alive?
0 · Reply
Merlintrader
Merlintrader Apr. 30 at 5:57 PM
$REVB Revelation Biosciences, Inc. (Nasdaq: $REVB): Gemini, AKI, CKD and the High-Risk Micro-Cap Repricing Setup https://www.merlintrader.com/revelation-biosciences-may2026-deepdive/
0 · Reply